Cerus Corporation (CERS)vsEdwards Lifesciences Corp (EW)
CERS
Cerus Corporation
$2.49
+1.22%
HEALTHCARE · Cap: $534.04M
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 2839% more annual revenue ($6.51B vs $221.55M). EW leads profitability with a 15.4% profit margin vs -3.1%. EW earns a higher WallStSmart Score of 55/100 (C).
CERS
Avoid27
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CERS.
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -9.7% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : CERS
CERS has a balanced fundamental profile.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : CERS
The primary concerns for CERS are EPS Growth, Market Cap, Debt/Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Key Dynamics to Monitor
CERS profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
CERS carries more volatility with a beta of 1.77 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 27/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cerus Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?